Thalidomide in the treatment of leprosy (Q34935353)

5 August 2017

1 reference

title

Thalidomide in the treatment of leprosy (English)

1 reference

5 August 2017

0 references

0 references

Steve K Teo

1

1 reference

5 August 2017

Ken E Resztak

2

1 reference

5 August 2017

Michael A Scheffler

3

1 reference

5 August 2017

Karin A Kook

4

1 reference

5 August 2017

Jerry B Zeldis

5

1 reference

5 August 2017

David I Stirling

6

1 reference

5 August 2017

Steve D Thomas

7

1 reference

5 August 2017

1 September 2002

1 reference

5 August 2017

Microbes and Infection

1 reference

5 August 2017

4

1 reference

5 August 2017

11

1 reference

5 August 2017

1193-1202

1 reference

THALIDOMIDE IN THE TREATMENT OF LEPRA REACTIONS

5 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS1286-4579%2802%2901645-3

7 January 2021

Drug susceptibility testing of Mycobacterium leprae in the BACTEC 460 system

1 reference

https://api.crossref.org/works/10.1016%2FS1286-4579%2802%2901645-3

7 January 2021

Massive gene decay in the leprosy bacillus

1 reference

https://api.crossref.org/works/10.1016%2FS1286-4579%2802%2901645-3

7 January 2021

Toxic effect of the peroxidase-hydrogen peroxide-halide antimicrobial system on Mycobacterium leprae

1 reference

https://api.crossref.org/works/10.1016%2FS1286-4579%2802%2901645-3

7 January 2021

Use of an Artificial Antigen Containing the 3,6-di-O-methyl- -D-glucopyranosyl Epitope for the Serodiagnosis of Leprosy

1 reference

https://api.crossref.org/works/10.1016%2FS1286-4579%2802%2901645-3

7 January 2021

Lymphocyte suppression in leprosy induced by unique M. leprae glycolipid

1 reference

https://api.crossref.org/works/10.1016%2FS1286-4579%2802%2901645-3

7 January 2021

Chemotherapy of leprosy

1 reference

https://api.crossref.org/works/10.1016%2FS1286-4579%2802%2901645-3

7 January 2021

Leprosy reactional states and their treatment

1 reference

https://api.crossref.org/works/10.1016%2FS1286-4579%2802%2901645-3

7 January 2021

The diagnosis and treatment of leprosy.

1 reference

https://api.crossref.org/works/10.1016%2FS1286-4579%2802%2901645-3

7 January 2021

Immunoprophylactic trial with combined Mycobacterium leprae/BCG vaccine against leprosy: preliminary results

1 reference

https://api.crossref.org/works/10.1016%2FS1286-4579%2802%2901645-3

7 January 2021

The significance of nerve involvement in leprosy

1 reference

https://api.crossref.org/works/10.1016%2FS1286-4579%2802%2901645-3

7 January 2021

Thalidomide selectively inhibits tumor necrosis factor alpha production by stimulated human monocytes

1 reference

https://api.crossref.org/works/10.1016%2FS1286-4579%2802%2901645-3

7 January 2021

Thalidomide in the treatment of erythema nodosum leprosum. With a note on selected laboratory abnormalities in erythema nodosum leprosum.

1 reference

https://api.crossref.org/works/10.1016%2FS1286-4579%2802%2901645-3

7 January 2021

Enhancement of phorbol ester-induced production of tumor necrosis factor alpha by thalidomide

1 reference

https://api.crossref.org/works/10.1016%2FS1286-4579%2802%2901645-3

7 January 2021

Thalidomide can be either agonistic or antagonistic to LPS evoked synthesis of TNF-alpha by mononuclear cells

1 reference

https://api.crossref.org/works/10.1016%2FS1286-4579%2802%2901645-3

7 January 2021

Tumor necrosis factor: status in reactions in leprosy before and after treatment

1 reference

https://api.crossref.org/works/10.1016%2FS1286-4579%2802%2901645-3

7 January 2021

Chronic bullous disease of childhood and ulcerative colitis.

1 reference

https://api.crossref.org/works/10.1016%2FS1286-4579%2802%2901645-3

7 January 2021

Thalidomide exerts its inhibitory action on tumor necrosis factor alpha by enhancing mRNA degradation

1 reference

https://api.crossref.org/works/10.1016%2FS1286-4579%2802%2901645-3

7 January 2021

Tumour necrosis factor-alpha (TNF-alpha) synthesis is associated with the skin and peripheral nerve pathology of leprosy reversal reactions

1 reference

https://api.crossref.org/works/10.1016%2FS1286-4579%2802%2901645-3

7 January 2021

Randomised comparison of thalidomide versus placebo in toxic epidermal necrolysis

1 reference

https://api.crossref.org/works/10.1016%2FS1286-4579%2802%2901645-3

7 January 2021

Immunomodulation by thalidomide and thalidomide analogues

1 reference

https://api.crossref.org/works/10.1016%2FS1286-4579%2802%2901645-3

7 January 2021

10.1016/S1286-4579(02)01645-3

Identifiers

DOI

1 reference

5 August 2017

1 reference